TMPRSS2 and prostate carcinoma: The fusion mutations from tumor samples appear to have various iFCR values and, interestingly, the well-studied prostate cancer fusion TMPRSS2-ERG was closed to the fusions of cancer cell lines and appears to have higher iFCR values and expression levels in all three independent patients.